Results 211 to 220 of about 693,900 (279)

PARP Inhibitors and the Risk of Serum Creatinine Elevation in Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

Cancers (Basel)
Gąsowska-Bodnar A, Gąsowska-Bajger B, Żołnierek A, Żołnierek J, Bodnar L.   +4 more
europepmc   +1 more source

Harnessing benzamides as plant stress inhibitors, growth promoters and in management of crop resilience—A review

Plant Biology, EarlyView.
Benzamides boost crop resilience by inhibiting poly(ADP‐ribose) polymerase (PARP) to enhance stress tolerance and, through their antimicrobial, herbicidal, and insecticidal derivatives, they offer broad protection for sustainable crop improvement. Abstract Benzamides have emerged as potent stress inhibitors and growth promoters in plant biotechnology ...
M. J. Koetle, T. E. Motaung, S. O. Amoo
wiley   +1 more source

Expert opinion on the management of anemia in prostate cancer patients receiving PARP inhibitors. [PDF]

Can Urol Assoc J
Hanna L, O'Dwyer R, Hamilou Z, Noonan K, Doucette S, Sridhar SS.   +5 more
europepmc   +1 more source

APOBEC3B enhances the efficacy of PARP inhibitors in elimination of ovarian cancer stem cell. [PDF]

Sci Rep
Rivera M, Liu L, Enlund S, Lim CE, Zhang H, Yang K, Sasik R, Crews LA, Fisch KM, Eskander RN, Holm F, Jiang Q.   +11 more
europepmc   +1 more source

Of mice and men—The emerging oral–gut–brain axis of health and disease

Periodontology 2000, EarlyView.
Abstract Objectives Oral health's inextricable links to systemic health are highlighted by the emerging oral–gut–brain axis and other well‐known axes. There is growing evidence of a complex oral–gut–brain axis linking mouth and gut microbiomes with the central nervous system.
Yvonne L. Hernandez‐Kapila, Daniel J. Weisenberger   +1 more
wiley   +1 more source

PARP Inhibitors in the Treatment of Prostate Cancer: An Analysis of the Clinical Trial Landscape. [PDF]

Cancer Med
Chen Y, Cao J, Huang R, Lou J, Gu J, Luo Z, Yao T, Xie J.   +7 more
europepmc   +1 more source

Hyperthermia‐induced cytotoxicity and modulation of PD‐L1 and MHC‐I expression in human non‐small cell lung cancer cell lines

Experimental Physiology, EarlyView.
Abstract Hyperthermia has recently been applied to treat human non‐small cell lung cancer (NSCLC). However, the mechanisms underlying cytotoxic sensitivity of NSCLC cells to hyperthermia are not fully understood. In this study, five NSCLC cell lines with different epidermal growth factor receptor (EGFR), Kirsten rat sarcoma and tumor protein p53 ...
Yun‐Chieh Tu, Wei‐Chen Yeh, Yi‐Wei Fang, Ko‐Hsuan Lo, Lei‐Ni Liang, Xu‐Chen Liu, Chia‐Chi Tsai, Chih‐Cheng Cheng, Meng‐Chieh Lin, Hsin‐Hsien Yu, Bor‐Chyuan Su   +10 more
wiley   +1 more source

MTUS2-AS1 suppression promotes DDX5 protein degradation to enhance the sensitivity of PARP inhibitors in BRCA-wild triple negative breast cancer. [PDF]

Int J Biol Sci
Xu T, Nie J, Pan B, Hong Q, Fan Y, Dong L, Qin J, Sun H, Xu M, Pan Y, Wang S.   +10 more
europepmc   +1 more source

Olaparib‐associated cutaneous vasculitis in a patient with breast cancer

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Marcial Álvarez‐Salafranca, Teresa Puértolas, Adrián Diago, María Carmen Gómez‐Mateo   +3 more
wiley   +1 more source

VEGF inhibitor‐induced vascular dysfunction involves redox‐sensitive PARP activation and SIRT1 disruption

Experimental Physiology, EarlyView.
Abstract Vascular endothelial growth factor receptor (VEGFR) inhibitors are effective antiangiogenic agents used in cancer therapy. However, they are associated with cardiovascular disease, including hypertension and vascular dysfunction. The molecular mechanisms underlying these cardiovascular toxicities are unclear, but oxidative stress might be ...
Karla B. Neves, Rheure Alves‐Lopes, Augusto C. Montezano, Rhian M. Touyz   +3 more
wiley   +1 more source